Two COVID Drugs Added to China’s Public Health Insurance Scheme

A closing checklist of medicine to be included in China’s public medical health insurance scheme was launched on January 18. During a press convention, China’s Healthcare Security Administration mentioned {that a}whole of 111 medication had been added to {the catalogue}, and that three medication had been dropped. There are actually 2,967 varieties of medicine within the scheme.

The four-day negotiations between Chinese regulators and pharmaceutical firms from January 5 to January 8 had been fruitful. The common value of newly admitted medication by negotiation and bidding has dropped by 60.1%. It is estimated that this adjustment will scale back the burden on sufferers by over 90 billion yuan ($13.28 billion) within the subsequent two years. This is the third 12 months that COVID-19 medication have been taken into the medical insurance coverage catalogue. Earlier, China’s Medical Products Administration introduced on January 8 that Azvudine and Qingfei Paidu granules had entered the medical health insurance scheme.

Azvudine, which was permitted for launch on July 25, 2022, will likely be bought at a value of 11.58 yuan per 3mg. The drug is split into two specs: 1mg and 3mg, and solely 1mg is permitted for the therapy of atypical grownup sufferers with COVID-19. The essential purpose is that the really useful dose for treating COVID-19 is 5mg for grownup sufferers. In order to make sure the dosage, Azvudine’s directions state that tablets shouldn’t be crushed.

Liu Yong, the vice chairman of Genuine Biotech, the developer of Azvudine, as soon as identified that the indications for the therapy of Azvudine in COVID-19 had been permitted in July final 12 months. The negotiation in January this 12 months solely includes the indications for the therapy of AIDS. “Although we are here to talk about the indications for AIDS this time, because the drug involves the COVID-19 treatment, the negotiation result will also affect the future pricing,” mentioned Liu.

SEE ALSO: Pfizer and Chinese Authorities Fail to Reach Deal on COVID Pill Paxlovid

Previously, Azvudine was briefly included within the scope of medical insurance coverage fee on the value of 270 yuan per bottle (35 tablets per bottle, 1mg per pill). After conversion, the worth per milligram of the drug is 7.71 yuan. After this medical insurance coverage negotiation, the worth per milligram is 3.86 yuan, which is decreased by about 50%.

Another COVID-19 drug, Qingfei Paidu, is a broadly used conventional Chinese medication, which was listed by emergency approval on March 2, 2021, and its manufacturing unit was Zhangzhou Pien Tze Huang Pharmaceutical Co., Ltd. Unlike different medication, Qingfei Paidu granule is the transformation of efficient prescriptions screened by many academicians and specialists in Wuhan, Huabei Province, the primary place that was hit by COVID-19 again in 2020.

Sign up as we speak for five free articles month-to-month!